Precision BioSciences Inc (DTIL)vsModerna Inc (MRNA)
DTIL
Precision BioSciences Inc
$6.26
+1.29%
HEALTHCARE · Cap: $171.68M
MRNA
Moderna Inc
$192.57
-5.35%
HEALTHCARE · Cap: $69.04B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 4845% more annual revenue ($2.23B vs $45.05M). DTIL leads profitability with a -117.0% profit margin vs -141.4%. DTIL earns a higher WallStSmart Score of 33/100 (F).
DTIL
Avoid33
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.2%
Fair Value
$13.23
Current Price
$6.26
$6.97 discount
Margin of Safety
+69.9%
Fair Value
$134.59
Current Price
$192.57
$57.98 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 37272.0% year-over-year
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -58.5% — below average capital efficiency
Trading at 11.4x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : DTIL
The strongest argument for DTIL centers on Revenue Growth. Revenue growth of 37272.0% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : DTIL
The primary concerns for DTIL are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
DTIL profiles as a hypergrowth stock while MRNA is a turnaround play — different risk/reward profiles.
DTIL carries more volatility with a beta of 1.25 — expect wider price swings.
DTIL is growing revenue faster at 37272.0% — sustainability is the question.
DTIL generates stronger free cash flow (-13M), providing more financial flexibility.
Bottom Line
DTIL scores higher overall (33/100 vs 21/100) and 37272.0% revenue growth. MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Precision BioSciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?